Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma
November 1st 2007Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.